|
(18S)-resolvin E1 |
|
CHEBI:137038 |
|
(18S)-resolvin E1 |
|
A resolvin that is (6Z,8E,10E,14Z,16E)-icosa-6,8,10,14,16-pentaenoic acid which is substituted at positions 5, 12 and 18 by hydroxy groups (the 5S,12R,18S stereoisomer). |
|
 
This entity has been manually annotated by the ChEBI Team.
|
|
Bijay
|
|
CHEBI:138498
|
|
ZINC000038214815 |
|
Molfile
XML
SDF
|
|
more structures >>
|
|
|
InChI=1S/C20H30O5/c1- 2- 17(21) 11- 8- 5- 9- 14- 18(22) 12- 6- 3- 4- 7- 13- 19(23) 15- 10- 16- 20(24) 25/h3- 9,11- 13,17- 19,21- 23H,2,10,14- 16H2,1H3,(H,24,25) /b4- 3+,9- 5- ,11- 8+,12- 6+,13- 7- /t17- ,18- ,19+/m0/s1 |
AOPOCGPBAIARAV-JJVMZPRHSA-N |
C(\[C@H](CCCC(O)=O)O)=C\C=C\C=C\[C@@H](C\C=C/C=C/[C@H](CC)O)O |
|
Bronsted acid
A molecular entity capable of donating a hydron to an acceptor (Bronsted base).
(via oxoacid )
|
|
human xenobiotic metabolite
Any human metabolite produced by metabolism of a xenobiotic compound in humans.
specialised pro-resolving mediator
A class of cell signaling molecules enzymatically derived from n-3 long chain polyunsaturated fatty acids that have important roles in orchestrating the resolution of tissue inflammation.
(via resolvin )
|
|
anti-inflammatory agent
Any compound that has anti-inflammatory effects.
specialised pro-resolving mediator
A class of cell signaling molecules enzymatically derived from n-3 long chain polyunsaturated fatty acids that have important roles in orchestrating the resolution of tissue inflammation.
(via resolvin )
|
|
View more via ChEBI Ontology
(5S,6Z,8E,10E,12R,14Z,16E,18S)- 5,12,18- trihydroxyicosa- 6,8,10,14,16- pentaenoic acid
|
(5S,12R,18S)- trihydroxy- (6Z,8E,10E,14Z,16E)- eicosapentaenoic acid
|
ChEBI
|
(5S,12R,18S)- trihydroxy- (6Z,8E,10E,14Z,16E)- icosapentaenoic acid
|
ChEBI
|
(5S,6Z,8E,10E,12R,14Z,16E,18S)- 5,12,18- trihydroxyicosapentaenoic acid
|
ChEBI
|
18S-resolvin E1
|
ChEBI
|
18S-RvE1
|
ChEBI
|
5S,12R,18S-trihydroxy-6Z,8E,10E,14Z,16E-eicosapentaenoic acid
|
LIPID MAPS
|
21206090
|
PubMed citation
|
Europe PMC
|
21712098
|
PubMed citation
|
Europe PMC
|
|